Zimelidine

Jump to: navigation, search
Zimelidine
Zimelidine Wiki Str.png
Clinical data
Pregnancy
category
  •  ?
Routes of
administration
Oral
ATC code
Legal status
Legal status
  • Withdrawn from market
Pharmacokinetic data
Bioavailability?
Metabolism?
Elimination half-life8.4 +/- 2.0 hours (parent compound)
19.4 +/- 3.6 hours (norzimelidine)
Excretion?
Identifiers
CAS Number
  • 56775-88-3 60525-15-7 (anhydrous dihydrochloride), 61129-30-4 (dihydrochloride monohydrate)
PubChem CID
E number{{#property:P628}}
ECHA InfoCard{{#property:P2566}}Lua error in Module:EditAtWikidata at line 36: attempt to index field 'wikibase' (a nil value).
Chemical and physical data
FormulaC16H17BrN2
Molar mass317.224

WikiDoc Resources for Zimelidine

Articles

Most recent articles on Zimelidine

Most cited articles on Zimelidine

Review articles on Zimelidine

Articles on Zimelidine in N Eng J Med, Lancet, BMJ

Media

Powerpoint slides on Zimelidine

Images of Zimelidine

Photos of Zimelidine

Podcasts & MP3s on Zimelidine

Videos on Zimelidine

Evidence Based Medicine

Cochrane Collaboration on Zimelidine

Bandolier on Zimelidine

TRIP on Zimelidine

Clinical Trials

Ongoing Trials on Zimelidine at Clinical Trials.gov

Trial results on Zimelidine

Clinical Trials on Zimelidine at Google

Guidelines / Policies / Govt

US National Guidelines Clearinghouse on Zimelidine

NICE Guidance on Zimelidine

NHS PRODIGY Guidance

FDA on Zimelidine

CDC on Zimelidine

Books

Books on Zimelidine

News

Zimelidine in the news

Be alerted to news on Zimelidine

News trends on Zimelidine

Commentary

Blogs on Zimelidine

Definitions

Definitions of Zimelidine

Patient Resources / Community

Patient resources on Zimelidine

Discussion groups on Zimelidine

Patient Handouts on Zimelidine

Directions to Hospitals Treating Zimelidine

Risk calculators and risk factors for Zimelidine

Healthcare Provider Resources

Symptoms of Zimelidine

Causes & Risk Factors for Zimelidine

Diagnostic studies for Zimelidine

Treatment of Zimelidine

Continuing Medical Education (CME)

CME Programs on Zimelidine

International

Zimelidine en Espanol

Zimelidine en Francais

Business

Zimelidine in the Marketplace

Patents on Zimelidine

Experimental / Informatics

List of terms related to Zimelidine

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Overview

Zimelidine (Normud®, Zelmid®) was the first marketed selective serotonin reuptake inhibitor (SSRI) antidepressant. It is a pyridylallylamine, structurally different from other antidepressants. The substance was developed in the early 1980s by the Swedish company Astra AB following a search for drugs with structures similar to chlorpheniramine (it is a derivative of Chlorphenamine), an antihistamine with antidepressant activity. It was then licensed to other drug producers.

Zimelidine has been banned worldwide due to serious, sometimes fatal, cases of central and/or peripheral neuropathy known as Guillain-Barré syndrome and due to a peculiar hypersensitivity reaction involving many organs including skin exanthema, flu-like symptoms, arthralgias, and sometimes eosinophilia. Additionally, zimelidine was charged to cause an increase in suicidal ideation and/or attempts among depressive patients. After its ban, it was succeeded by fluvoxamine and fluoxetine (derived from the antihistamine diphenhydramine) in that order, and the other SSRIs.

Mechanism of action

The mode of action is a strong reuptake inhibition of serotonin from the synaptic cleft. Postsynaptic receptors are not acted upon.

Other uses

Zimelidine was reported by Montplaisir and Godbout to be very effective for cataplexy in 1986, back when this was usually controlled by tricyclic antidepressants, which often had anticholinergic effects.[2] Zimelidine was able to improve cataplexy without causing daytime sleepiness.[3]

Side effects

Most often reported were:

Interactions

Dosage

The former doses were 200 to 400mg daily in outpatients and up to 600mg in inpatients.

References

  1. ^ Caille G, Kouassi E, de Montigny C. (1986). "Pharmacokinetic study of zimelidine using a new GLC method". Clinical Pharmacokinetics. 8 (6): 530–40. PMID 6228368.
  2. ^ Godbout R, Montplaisir J. (1986). "The effect of zimelidine, a serotonin-reuptake blocker, on cataplexy and daytime sleepiness of narcoleptic patients". Clinical Neuropharmacology. 9 (1): 46–51. PMID 2950994.
  3. ^ see Godbout et al. 1986



Linked-in.jpg